AVLN (Avalyn Pharma) Debt-to-EBITDA : (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AVLN Avalyn Pharma Inc AVLN
12 GF Score
Price $31.35
View Full Analysis

What is Avalyn Pharma Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Avalyn Pharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was $0.82 Mil. Avalyn Pharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was $16.29 Mil. Avalyn Pharma's annualized EBITDA for the quarter that ended in Jun. 2026 was $-114.21 Mil. Avalyn Pharma's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2026 was -0.15.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Avalyn Pharma's Debt-to-EBITDA or its related term are showing as below:

AVLN' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.31   Med: -0.02   Max: -0.02
Current: -0.31

During the past 2 years, the highest Debt-to-EBITDA Ratio of Avalyn Pharma was -0.02. The lowest was -0.31. And the median was -0.02.

AVLN's Debt-to-EBITDA is ranked worse than
100% of 304 companies
in the Biotechnology industry
Industry Median: 1.215 vs AVLN: -0.31

Avalyn Pharma  (NAS:AVLN) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Avalyn Pharma Debt-to-EBITDA Related Terms

Avalyn Pharma Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for Avalyn Pharma's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Avalyn Pharma Debt-to-EBITDA Chart

Avalyn Pharma Annual Data
Trend Dec24 Dec25
Debt-to-EBITDA
- -

Avalyn Pharma Quarterly Data
Mar25 Jun25 Mar26 Jun26
Debt-to-EBITDA - - - -

AVLN vs LBRX, LTGO, NVAX: Debt-to-EBITDA Comparison

For the Biotechnology subindustry, Avalyn Pharma's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Avalyn Pharma Debt-to-EBITDA vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Avalyn Pharma's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Avalyn Pharma's Debt-to-EBITDA falls into.


AVLN
12GF Score
Avalyn Pharma Inc AVLN
Debt-to-EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Avalyn Pharma Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Avalyn Pharma's Debt-to-EBITDA for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.444 + 1.225) / -85.162
=-0.02

Avalyn Pharma's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2026 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.816 + 16.293) / -114.212
=-0.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.

Avalyn Pharma Business Description

Address 105 W First Street, Boston, MA, USA, 02127
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.
12GF Score

Get the complete analysis for AVLN

Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$31.35
Price